Clinical globalization: A case study of privately-sponsored HIV research in Mexico

Social Identities

Volumn 14, Issue 2, 2008, Pages 189-213

  Leger, Marie Claire ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Clinical trials; Globalization; HIV AIDS; Medical research; Mexico; Pharmaceutical industry

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GLOBALIZATION; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACEUTICAL INDUSTRY; POLITICAL ECONOMY; RESEARCH WORK;

MEXICO [NORTH AMERICA]; NORTH AMERICA;

EID: 40949141868     PISSN: 13504630     EISSN: 13630296     Source Type: Journal    
DOI: 10.1080/13504630801933050     Document Type: Article

References (108)

1. Anderson, W. (2006) Colonial pathologies: American tropical medicine, race, and hygiene in the Philippines, Duke University Press, London, UK
2. Ángeles-Llerenas, A., Bello, M. A., Dirce, G. and Salinas, M. A. (2004) Argentina, Brasil, y México. La investigación biomédica y la defensa de un único estándar de atención en países en desarrollo. Revista de Investigación Clinica, 56:5, pp. 675-685.
3. Aoki, N. (2000) Lack of human subjects a bitter pill for drug makers to avoid costly delays, firms turning to ads, internet, consultants. The Boston Globe
4. Arnold, D. (1993) Colonizing the body: State medicine and epidemic disease in nineteenth-century India, University of California Press, Berkeley, CA
5. Bautista-Arredondo, S., Mane, A. and Bertozzi, S. M. (2006) Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: Lessons from Mexico. AIDS, 20:1, pp. 101-109.
6. Benatar, S. R. (1998) Imperialism, research ethics, and global health. Journal of Medical Ethics, 24, pp. 221-222.
7. Beverage Marketing Corporation (2001) Rapid growth characterizes Mexican beverage market according to new Beverage Marketing Corporation report.
8. Biehl, J., Coutinho, D. and Outeiro, A. L. (2001) Technology and affect: HIV/AIDS testing in Brazil. Culture, Medicine, and Psychiatry, 25:1, pp. 87-129.
9. Birn, A. E. and Solórzano, A. (1999) Public health paradoxes: Science and politics in the Rockefeller Foundation's hookworm campaign in Mexico in the 1920s. Social Science and Medicine, 49:9, pp. 1197-1213.
10. Borger, J. (2001) Dying for drugs: Volunteers or victims? Concern grows over control of drug trials. The Guardian
11. Braithwaite, J. (1984) Corporate crime in the pharmaceutical industry, Routledge & Kegan Paul, London, UK
12. Braithwaite, J. and Drahos, P. (2000) Global business regulation, Cambridge University Press, Cambridge, UK
13. Briggs, L. (2002) Reproducing empire: Race, sex, science, and US imperialism in Puerto Rico, The University of California Press, Berkeley, CA
14. Carrillo, H. (2002) The night is young: Sexuality in Mexico in the time of AIDS, University of Chicago Press, Chicago, IL
15. Casper, M. (1998) The making of the unborn patient: A social anatomy of fetal surgery, Rutgers University Press, New Brunswick, NJ
16. Centro Nacional de la Prevención y Control del SIDA, Rodríguez, C. Magis, Bravo-García, E. and Zúñiga, P. Uribe (2002) Dos décadas de la epidemia del SIDA en México.
17. Centro Nacional para la Prevención y Control del VIH/SIDA (CENSIDA), & Secretara de Salud (2001) Programa de acción para la prevención y control del VIH/sida e ITS 2001-2006.
18. Christakis, N. A. (1992) Ethics are local: Engaging cross-cultural variation in the ethics for clinical research. Social Science and Medicine, 35:9, pp. 1079-1091.
19. Cohen, L. (1999) Where it hurts: Indian material for an ethics of organ transplantation. Daedalus, 128:4, pp. 135-166.
20. Cruz, A. (2002) En el D.F., más casos de SIDA que los declarados.
21. (1994) Missionaries of science: The Rockefeller Foundation and Latin America, Indiana University Press, Bloomington, IN
22. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, & Center of Devices and Radiological Health (2001) Guidance for industry: Acceptability of foreign clinical studies.
23. Department of Health and Human Services, Office of Inspector General (2001) The globalization of clinical trials: A growing challenge in protecting human subjects
24. Department of Health and Human Services, Office of Inspector General (2000) Recruiting human subjects: Pressures in industry sponsored clinical research
25. DeYoung, K. and Nelson, D. (2000) Latin America is ripe for trials and fraud: Frantic pace could overwhelm trials. Washington Post
26. Duster, T. (2003) Backdoor to eugenics, Routledge, New York, NY
27. Eckman, A. (1998) Beyond 'The Yentl Syndrome': Making women visible in post-1990 women's health discourse. Visible woman: Imaging technologies, gender, and science, pp. 130-168. New York University Press, New York
28. Epstein, S. (1996) Impure science: AIDS, activism, and the politics of knowledge, University of California Press, Berkeley, CA
29. European Agency for the Evaluation of Medicinal Products (EMEA) (2001) Committee for proprietary medicinal products 26 to 28 June 2001 Plenary Meeting.
30. Farmer, P. and Campos, N. Gastineau (2004) Rethinking medical ethics: A view from below. Developing World Bioethics, 4:1, pp. 17-41.
31. Flaherty, M. P., Nelson, D. and Stephens, J. (2000) The body hunters: Overwhelming the watchdogs. The Washington Post
32. Food and Drug Administration (2004) Human subject protection; foreign clinical studies not conducted under an investigational new drug application. Federal Register
33. Franklin, S. (2003) Ethical biocapital: New strategies of cell culture. Remaking life and death: Toward an anthropology of the biosciences, pp. 97-127. School of Social Research Press, Santa Fe, NM
34. Díaz, F. Galván (1988) El SIDA en México: Los efectos sociales, Ediciones de Cultura Popular, Universidad Autónoma Metropolitana, Azcapotzalco, Mexico City
35. de León, C. García and Parco, N. Díaz (1999) El acceso a tratamientos para VIH/SIDA en Mevxico desde la perspectiva de la sociedad civil, Laccasso & UNAIDS, Buenos Aires, Argentina
36. Villanueva, C. García and Quintana, S. Perera (1982) La industria farmacéutica en América Latina, IMMS, Secretaría General, Mexico City
37. Garrafa, V. and Prado, M. Machado do (2001) Mudanças na Declaração de Helsinki: Fundamentalismo econômico, imperialismo ético, e controle social. Cadernos de Saúde Pública, 17:6, pp. 1489-1496.
38. Gereffi, G. (1983) The pharmaceutical industry and dependency in the Third World, Princeton University Press, Princeton, NJ
39. González-Rossetti, A. and Mogollon, O. (2000) Enhancing the political feasibility of health reform: The Mexico case.
40. Greco, D. B. (2004) Revisiting Helsinki [Letter]. Canadian Medical Association Journal, 170:1, pp. 20-21.
41. Greider, W. (1997) One world, ready or not: The manic logic of global capitalism, Simon and Schuster, New York, NY
42. Hacking, I. (1986) Making up people. Reconstructing individualism: Autonomy, individuality and the self in Western thought, pp. 222-236. Stanford University Press, Stanford, CA
43. Halpern, S. A. (2001) Constructing moral boundaries: Public discourse on human experimentation in twentieth-century America. Bioethics in social context, pp. 69-89. Temple University Press, Philadelphia, PA
44. Harvey, D. (1989) The condition of postmodernity: An enquiry into the origins of cultural change, Blackwell Publishing, Oxford, UK
45. Hayden, C. (2003) When nature goes public: The making and unmaking of bioprospecting in Mexico, Princeton University Press, Princeton, NJ
46. Hirsch, J., Meneses, S., Thompson, B., Negroni, M., Pelcastre, B. and Rio, C. del (2007) The inevitability of infidelity: Sexual reputation, social geographies, and marital HIV risk in rural Mexico. American Journal of Public Health, 97:6, pp. 986-996.
47. Hornblum, A. M. (1998) Acres of skin: Human experimentation at Holmesburg Prison, Routledge, New York, NY
48. Siqueiros, J.R. Huerdo (2000) The role of community mobilization in the access to antiretrovirals in Latin America and the Caribbean. AIDS in Latin America and the Caribbean: A multidisciplinary view
49. Human, D. and Fluss, S. S. (2001) The World Medical Association's Declaration of Helsinki: Historical and contemporary perspectives.
50. IMS Health (2004) Lipitor leads the way in 2003.
51. IMS Health (2006) Changing market dynamics in 2007.
52. International Conference on Harmonization (1996) Guideline for good clinical practice.
53. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2004) UNAIDS 2004 Report on the global AIDS epidemic
54. Jonsen, A. R. (1998) The birth of bioethics, Oxford University Press, New York, NY
55. Katz, J., Burachik, G., Brodovsky, J. and de Queiroz, S. R. R. (1997) Apertura económica y desregulación en el mercado de medicamentos: La industria farmacéutica y farmoquímica de Argentina, Brasil, y México en los años 90, CEPAL/IDRC, Alianza Editorial, Buenos Aires, Argentina
56. Kleinman, A. (1999) Moral experience and ethical reflection: Can ethnography reconcile them? A quandry for the new bioethics. Daedalus, 129:4, pp. 69-98.
57. Kloppenburg, J. R. (2005) First the seed: The political economy of plant biotechnology, University of Wisconsin Press, Madison, WI
58. Kottow, M. H. (2005) Conflictos en ética de investigación con seres humanos. Cadernos de Saúde Pública, 21:3, pp. 862-869.
59. Carré, J. Le (2001) The constant gardener, Scribner, New York, NY
60. Lederer, S. (1995)Johns Hopkins University Press, Baltimore, MD
61. López-Arellano, O. and Blanco-Gil, J. (2001) La polarización de la política de salud en México. Cadernos de Saúde Pública, 17:1, pp. 43-54.
62. Lurie, P. and Greco, D. B. (2005) US exceptionalism comes to research ethics. The Lancet, 365:9465, pp. 1117-1119.
63. Lurie, P. and Wolfe, S. (1997) Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. NEJM, 337:12, pp. 853-856.
64. Lustgarten, A. (2005) Drug testing goes offshore. Fortune
65. Marcelo, R. (2003) India beckons as a test-bed for western drug companies: Groups see the chance for big savings but questions are raised about the ethics of trials on illiterate patients. Financial Times
66. Marks, H. M. (1997) The progress of experiment: Science and therapeutic reform in the United States, 1900-1990, Cambridge University Press, Cambridge, UK
67. Marks, L. V. (2001) Sexual chemistry: A history of the contraceptive pill, Yale University Press, New Haven, CT
68. Marshall, P. A. (2001) Informed consent in international health care research. Biomedical research ethics: Updating international guidelines: A consultation, pp. 100-134. Council for International Organization of Medical Sciences (WHO), Geneva
69. Mirowski, P. and Van Horn, R. (2005) The contract research organization and the commercialization of scientific research. Social Studies of Science, 35:4, pp. 503-548.
70. Salazar, R.E. Molina and Murillo, V.M. Soria (1984) La industria farmacéutica en México: Inversión extranjera y sobrefacturación, Centro de Investigación para la Integración Social, San Angel, Mexico
71. Notiese (2000) Demandan al IMSS abasto de medicamentos antivirales. Letra S, La Jornada
72. Organization for Economic Cooperation and Development (OECD) (2003) Health at a glance - OECD indicators 2003, country notes, Mexico.
73. Oudshoorn, N. (1994) Beyond the natural body: An archeology of sex hormones, Routledge, London
74. Pan American Health Organization (PAHO) (2000)
75. Pan American Health Organization (PAHO) (2002) Profile of the health services system: Mexico
76. Peterson, M. (2002) Madison Avenue has growing role in the business of drug research. The New York Times
77. Petryna, A. (2002) Life exposed: Biological citizens after Chernobyl, Princeton University Press, Princeton, NJ
78. Petryna, A. (2005) Ethical variability: Drug development and globalizing clinical trials. American Ethnologist, 32:2, pp. 183-197.
79. Pharmaceutical Research and Manufacturers of America (PhRMA) (2001) PhRMA discussion paper on the Declaration of Helsinki as revised in October 2000.
80. Prakash, G. (1999) Another reason: Science and the imagination of modern India, Princeton University Press, Princeton, NJ
81. Public Citizen (2001)
82. Rabinow, P. (1996) Essays on the anthropology of reason, Princeton University Press, Princeton, NJ
83. Rapp, R. (1999) Testing women, testing the fetus: The social impact of amniocentesis in America, Routledge, New York
84. Reardon, T. and Berdegue, J. A. (2002) The rapid rise of supermarkets in Latin America: Challenges and opportunities for development. Development Policy Review, 20:4, pp. 371-388.
85. Rose, N. (1999) Powers of freedom: Reframing political thought, Cambridge University Press, Cambridge, UK
86. Rothman, D. J. (1991) Strangers at the bedside: A history of how law and bioethics transformed medical decision making, Basic Books, New York
87. Rothman, D. J. (2000) The shame of medical research. The New York Review of Books, 47, pp. 60-64.
88. Rowland, C. (2003) US drug companies are conducting more clinical trials overseas, study finds. Boston Globe
89. Saavedra, J. (2000) The process of access to anti-retroviral therapy in Mexico: Case Study.
90. López, J.A. Saavedra and Rodríguez, C. Magis (1998) Costos y gastos en atención médica del SIDA en México, CONASIDA, Mexico City
91. Scheper-Hughes, N. (2000) The global traffic in human organs. Current Anthropology, 41:2, p. 191.
92. Secretaría de Salud (SSA) (2003) México es un modelo a seguir en materia de prevención y control del VIH/Sindrome de Inmunodeficiencia Adquirida SIDA.
93. Secretaría de Salud (SSA) (2006) Panorama Epidemiológico del VIH/SIDA e ITS en México.
94. Sell, S. K. (2003) Private power, public law: The globalization of intellectual property rights, Cambridge University Press, Cambridge, UK
95. Shah, S. (2002) Globalizing clinical research. The Nation
96. Shiva, V. (1997) Biopiracy: The plunder of nature and knowledge, South End Press, Boston, MA
97. Slater, J. (2004) India emerges as new drug proving ground. Wall Street Journal
98. Soto-Laveaga, G. (2001) Root of discord: Steroid hormones, a wild yam, 'peasants', and state formation in Mexico.
99. (2002) Subsecretaria de Prevención y Protección de la Salud Centro Nacional para la Prevención y Control del VIH/SIDA.
100. Sung, N., Crowley, W. F., Genel, M., Salber, P., Sandy, L., Sherwood, L. M., Johnson, S. B., Catanese, V., Tilson, H., Getz, K., Larson, E. L., Scheinberg, D., Reece, E. A., Slavkin, H., Dobs, A., Grebb, J., Martinez, R. A., Korn, A. and Rimoin, D. (2003) Central challenges facing the national clinical research enterprise. JAMA, 289:10, pp. 1278-1287.
101. Thompson, C. (2005) Making parents: The ontological choreography of reproductive technologies, MIT Press, Cambridge, MA
102. Treichler, P. (1999) How to have theory in an epidemic: Cultural chronicles of AIDS, Duke University Press, Durham, NC
103. Turner, L. (1998) An anthropological exploration of contemporary bioethics: The varieties of common sense. Journal of Medical Ethics, 24:2, pp. 127-133.
104. UNAIDS (2006) Fact Sheet: Latin America.
105. UNAIDS (2005) AIDS epidemic update: Latin America.
106. WHO and industry combine to form ethics body (2002) Nature Medicine, 8:7, p. 645.
107. World Health Organization (WHO) (2000) Operational guidelines for ethics committees that review biomedical research.
108. World Medical Association (WMA) (2000) Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 284:23, pp. 3043-3045.